Vimarsana
Biggest News Aggregation in the World

Page 19 - Daniel Vitt News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Daniel Vitt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Daniel Vitt Today - Breaking & Trending Today

DGAP-News: Immunic, Inc. to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference Seite 1 - Vimarsana News

DGAP-News: Immunic, Inc. to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference Seite 1

02.08.2022 - Issuer: Immunic, Inc. / Key word(s): Conference Immunic, Inc. to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference 02.08.2022 / 12:30 The issuer is solely responsible for the content of this announcement. Immunic, Inc. to ... Seite 1

DGAP-News: Immunic, Inc. to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference - Vimarsana News

DGAP-News: Immunic, Inc. to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference

Issuer: Immunic, Inc. / Key word(s): Conference Immunic, Inc. to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference 02.08.2022 / 12:30 The issuer is solely responsible

Immunic, Inc. to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference - Vimarsana News

Immunic, Inc. to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...

DGAP-News: Immunic, Inc.: Immunic Announces Publication of Data From Its Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in Peer Reviewed Journal, Annals of Clinical and Translational N - Vimarsana News

DGAP-News: Immunic, Inc.: Immunic Announces Publication of Data From Its Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in Peer Reviewed Journal, Annals of Clinical and Translational N

Issuer: Immunic, Inc. / Key word(s): Scientific publication/Study results Immunic Announces Publication of Data From Its Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting

Immunic Announces Publication of Data From Its Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in Peer Reviewed Journal, Annals of Clinical and Translational Neurology - Vimarsana News

Immunic Announces Publication of Data From Its Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in Peer Reviewed Journal, Annals of Clinical and Translational Neurology

NEW YORK, June 15, 2022 /PRNewswire/ -- Immunic, Inc. , a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic... | June 15, 2022